On Monday, U.S. stocks closed higher, with surging technology stocks pushing the Nasdaq 100 Index (+306 points or 2.88% to 10952) to another record close. The Dow Jones Industrial Average added 8 points to 26680, and the S&P 500 rose 27 points (+0.84%) to 3251.
Nasdaq 100 Index: Daily Chart
Source: GAIN Capital, TradingView
Market sentiment was boosted by positive trial results from several potential COVID-19 vaccines.
Retailing (+4.46%), Software & Services (+3.16%) and Semiconductors & Semiconductor Equipment (+2.25%) sectors perform the best. Amazon.com (AMZN +7.93%), Citrix Systems (CTXS +7.64%), Adobe Systems (ADBE +5.28%) and Microsoft (MSFT +4.30%) were among the top gainers.
Chevron (CVX -2.2%) said it has agreed to buy Noble Energy (NBL +5.44%) for $5 billion in an all-stock deal.
On the technical side, about 53.4% (52.2% in the prior session) of stocks in the S&P 500 Index were trading above their 200-day moving average, and 81.2% (80.4% in the prior session) were trading above their 20-day moving average.
European stocks were broadly higher. The Stoxx Europe 600 Index rose 0.75%. Germany's DAX 30 jumped 0.99%, France's CAC 40 climbed 0.47%, while the U.K.'s FTSE 100 eased 0.46%.
The benchmark U.S. 10-year Treasury yield drifted lower to 0.615%.
Spot gold price was up for a second session rising $7.00 (+0.4%) to $1,817 an ounce.
U.S. WTI crude oil futures (August) settled 0.5% higher at $40.81 a barrel, lifted by growing risk-on appetite.
On the forex front, the ICE U.S. Dollar Index slipped 0.1% on day to 95.82, the lowest level since March.
EUR/USD gained 0.2% to 1.1453. European Council President Charles Michel said he is confident that agreement on the bloc's stimulus package can be reached after putting forward a new proposal.
GBP/USD rose 0.7% to 1.2660.
USD/JPY climbed 0.2% to 107.25.
From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.